Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line study of IN10018 + garsorasib versus standard therapy in KRAS G12C-mutant advanced nonsquamous non-small cell lung cancer
CTR20253319Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ifebemtinib, garsorasib in non-small cell lung cancer (NSCLC), sponsored by InnoCare Pharma. Started Dec 2025; status: active.
02
Drugs
ifebemtinibgarsorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253319.